TriVentures

TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

BioProtect Ltd. is an international medical device startup founded in 2004 and headquartered in Israel, with subsidiaries in Germany and the United States. The company specializes in the development and commercialization of biodegradable balloon spacers designed to protect normal tissue during radiation therapy for cancer. Its flagship product, the ProSpace balloon spacer, has received CE marking and demonstrates superior efficacy and safety in safeguarding the rectum during prostate cancer radiation therapy. By creating a temporary separation between the rectum and targeted tissues, BioProtect's technology significantly reduces the risk of serious and chronic side effects associated with radiation treatment while enhancing tumor control. Additionally, the company's platform of biodegradable implantable balloons addresses a variety of unmet clinical needs in the growing radiotherapy spacers market.

FeelBetter is a healthcare optimization platform founded in 2018 and based in Tel Aviv, Israel. The company focuses on value-based models to identify at-risk patients and appropriate interventions. Its platform enhances financial and clinical outcomes by analyzing individual patients' health journeys and diagnosing necessary interventions before deterioration occurs. By delivering personalized data and actionable insights, FeelBetter enables healthcare organizations to improve patient outcomes and overall business results.

FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.

Genoox, Ltd. is a company that develops a cloud-based platform dedicated to managing and analyzing genomic data. Founded in 2014 by Amir Trabelsi and Moshe Einhorn, the company is headquartered in Palo Alto, California. Genoox's platform harnesses artificial intelligence and machine-learning algorithms to translate complex genetic information into actionable clinical insights, thereby facilitating genetic diagnostics and personalized treatment options for patients. The platform connects clinicians, genetic counselors, and healthcare organizations, creating a collaborative network that enhances the sharing of genetic insights. With over 1,700 health organizations, hospitals, and medical facilities utilizing its services across 44 markets globally, Genoox aims to establish the largest real-world evidence network of genomic and clinical data, ultimately improving patient outcomes through more effective and efficient data handling.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

BioProtect Ltd. is an international medical device startup founded in 2004 and headquartered in Israel, with subsidiaries in Germany and the United States. The company specializes in the development and commercialization of biodegradable balloon spacers designed to protect normal tissue during radiation therapy for cancer. Its flagship product, the ProSpace balloon spacer, has received CE marking and demonstrates superior efficacy and safety in safeguarding the rectum during prostate cancer radiation therapy. By creating a temporary separation between the rectum and targeted tissues, BioProtect's technology significantly reduces the risk of serious and chronic side effects associated with radiation treatment while enhancing tumor control. Additionally, the company's platform of biodegradable implantable balloons addresses a variety of unmet clinical needs in the growing radiotherapy spacers market.

TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Genoox, Ltd. is a company that develops a cloud-based platform dedicated to managing and analyzing genomic data. Founded in 2014 by Amir Trabelsi and Moshe Einhorn, the company is headquartered in Palo Alto, California. Genoox's platform harnesses artificial intelligence and machine-learning algorithms to translate complex genetic information into actionable clinical insights, thereby facilitating genetic diagnostics and personalized treatment options for patients. The platform connects clinicians, genetic counselors, and healthcare organizations, creating a collaborative network that enhances the sharing of genetic insights. With over 1,700 health organizations, hospitals, and medical facilities utilizing its services across 44 markets globally, Genoox aims to establish the largest real-world evidence network of genomic and clinical data, ultimately improving patient outcomes through more effective and efficient data handling.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, CathWorks aims to transform coronary angiography from subjective visual assessments into an objective decision-making tool. The company's flagship product, CathWorks FFRangio, is a non-invasive device that provides multi-vessel physiologic measurements, allowing physicians to optimize and confirm PCI therapy decisions during procedures. By leveraging functional flow reserve (FFR) data and automated algorithms, CathWorks enhances the use of coronary angiography data, promoting measurement-based medicine and improving operational efficiency in cath labs.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, specializing in healthcare equipment for colorectal surgeries. Established in 2010, Colospan develops proprietary technology aimed at preventing anastomotic leaks and the need for diverting colonic stomas after intestinal surgeries. The company’s lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site, thereby mitigating the complications associated with such leaks. This innovative device is intended to prevent or delay the need for colostomy after surgeries performed for severe intestinal inflammatory diseases and colorectal cancer. Colospan’s technology seeks to enhance patient recovery by reducing the risk of life-threatening symptoms associated with clinical anastomotic leaks and minimizing post-operative complications, ultimately supporting the well-being of patients following significant surgical procedures.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, specializing in healthcare equipment for colorectal surgeries. Established in 2010, Colospan develops proprietary technology aimed at preventing anastomotic leaks and the need for diverting colonic stomas after intestinal surgeries. The company’s lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site, thereby mitigating the complications associated with such leaks. This innovative device is intended to prevent or delay the need for colostomy after surgeries performed for severe intestinal inflammatory diseases and colorectal cancer. Colospan’s technology seeks to enhance patient recovery by reducing the risk of life-threatening symptoms associated with clinical anastomotic leaks and minimizing post-operative complications, ultimately supporting the well-being of patients following significant surgical procedures.

EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.

OrthoSpace Ltd. is an Israeli company that specializes in the development and commercialization of biodegradable balloon systems designed for the orthopedic market, specifically targeting rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating effective solutions that alleviate pain, improve patients' range of motion, and preserve bone and joint structures. Its flagship product, InSpace™, has received CE marking and is marketed in Europe. This innovative balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head, which facilitates smooth movement and reduces friction between the bones. OrthoSpace operates under the umbrella of Stryker Corporation, enhancing its capabilities in delivering advanced orthopedic solutions.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

OrthoSpace Ltd. is an Israeli company that specializes in the development and commercialization of biodegradable balloon systems designed for the orthopedic market, specifically targeting rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating effective solutions that alleviate pain, improve patients' range of motion, and preserve bone and joint structures. Its flagship product, InSpace™, has received CE marking and is marketed in Europe. This innovative balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head, which facilitates smooth movement and reduces friction between the bones. OrthoSpace operates under the umbrella of Stryker Corporation, enhancing its capabilities in delivering advanced orthopedic solutions.

EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.

FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.